Exposure and data collection points (delivery=0 time point) | Research visit (weeks) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
0 | 1 | 6 | 10 | 14 | 24 | 36 | 48 | 72 | 96 | |
a) Infant in utero exposures | ||||||||||
1. HIV exposure in utero/ postpartum | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
2. Antenatal dysbiosis, microbiome | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
3. Congenital co-infections; HBV, HCV, CMV, syphilis | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
4. Alcohol exposure (foetal alcohol syndrome) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
5. Food quantity and quality, antenatal diet, maternal BMI | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
6. Allergens, food, animal dander | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
7. Indoor pollution (paraffin stove cooking in one room/smoker) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
8. Household factors water/sanitation (quantity/quality)/ | ✓ | ✓ | ✓ | |||||||
b) Delivery & Postpartum Data | ||||||||||
1. Delivery date, gender, SGA, Apgar score, congenital abnormalities | ✓ | |||||||||
2. Weight, head circumference and length (MUAC from 6 weeks) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
3. Infant morbidity, sick clinic visits, hospitalisations, atopic dermatitis | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
4. Infant mortality | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
5. EPI immunisation compliance | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
6. Any medication being taken | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
c) Infant developmental assessment tools | ||||||||||
1. Denver tool | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||
2. Mullen tool (neurodevelopmental sub-study) | ✓ | ✓ | ✓ | ✓ | ✓ | |||||
d) Biological specimen collection | ||||||||||
1. Cord blood | ✓ | |||||||||
2. Blood and dried blood spots | ||||||||||
a) Vertical transmission of HIV, CMV, HBV, syphilis | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
b) EPI vaccine titres | ✓ | ✓ | ✓ | ✓ | ||||||
c) Plasma immune activation biomarkers | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
d) Systemic plasma Inflammation biomarkers and trends | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
e) Endothelial dysfunction biomarkers | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
f) Immunometabolomics | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
g) Biomarkers of intestinal structure and function (permeability, microbial translocation) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
h) Food allergens and atopic dermatitis sensitisation trends | ✓ | ✓ | ✓ | ✓ | ||||||
i) Full blood counts and clinical biochemistry | ✓ | ✓ | ✓ | |||||||
j) HIV viral load (in infected individuals) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
k) Pathogen genetic diversity and Host infection genetics | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |